Letter from the ESC Congress Programme Committee Chair

Dear Colleagues,

We are delighted to present this issue of ESC Congress 2017 in Review, focused on coronary artery disease (CAD) and acute coronary syndromes (ACS), two entities of particular importance in cardiology. The peer-reviewed highlights in this issue are based on presentations at the European Society of Cardiology (ESC) Congress 2017 held in Barcelona, Spain.

Among the articles in this issue, you will find a closer look at 2017 ESC Clinical Practice Guidelines on acute myocardial infraction (AMI) in patients presenting with persistent ST-segment elevation, which harbours significant changes to the previous version, both regarding acute care as well as long-term drug therapy.

Several Hot Line trials are covered in this issue. They include COMPASS, CANTOS, and RE-DUAL PCI. Results from RE-DUAL PCI showed that dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor was superior to triple therapy with warfarin at preventing bleeding after percutaneous coronary intervention among AF patients. COMPASS demonstrated that in high-risk patients with CAD rivaroxaban 2.5 mg BID plus aspirin 100 mg QD reduces the composite of cardiovascular death, stroke, or MI compared with aspirin alone. Data from the CANTOS trial showed that canakinumab reduces cardiovascular event rates and potentially reduces the rate of incident lung cancer as well as lung cancer mortality.

We are confident that the articles and practical perspectives presented in ESC Congress 2017 in Review - Focus on CAD and ACS will provide you with important new insights. To access ESC Congress content (videos, slides, abstracts, reports, and ESC TV interviews) all year long, visit us online at any time at www.escardio.org/365.

We hope to see you in Munich for ESC Congress 2018. For more information, please visit www.escardio.org/ESC2018.

Professor Stephan Achenbach, FESC
Chairman, ESC Congress Programme Committee 2016-2018



Posted on 30 August, 201717 March, 2021